Ionis Pharmaceuticals, Inc. (IONS) Director Joseph Klein III Sells 3,000 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Joseph Klein III sold 3,000 shares of the business’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $53.55, for a total transaction of $160,650.00. Following the transaction, the director now owns 12,939 shares in the company, valued at $692,883.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Joseph Klein III also recently made the following trade(s):

  • On Wednesday, November 15th, Joseph Klein III sold 2,250 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $53.56, for a total transaction of $120,510.00.
  • On Monday, November 13th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $55.39, for a total transaction of $166,170.00.

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) traded up $1.44 during mid-day trading on Friday, hitting $56.93. 1,149,432 shares of the company were exchanged, compared to its average volume of 1,468,307. The stock has a market cap of $7,080.00, a PE ratio of 352.87 and a beta of 2.89. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50. Ionis Pharmaceuticals, Inc. has a 12 month low of $37.26 and a 12 month high of $65.51.

A number of research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $68.00 target price on the stock in a research note on Tuesday, October 17th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 target price on shares of Ionis Pharmaceuticals in a research note on Tuesday, October 17th. Stifel Nicolaus reiterated a “hold” rating and issued a $50.00 target price on shares of Ionis Pharmaceuticals in a research note on Friday, October 13th. Goldman Sachs Group reiterated a “sell” rating and issued a $30.00 target price on shares of Ionis Pharmaceuticals in a research note on Friday, October 6th. Finally, Barclays assumed coverage on shares of Ionis Pharmaceuticals in a research note on Wednesday, September 6th. They issued an “equal weight” rating and a $55.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $50.31.

Several hedge funds have recently made changes to their positions in IONS. Steward Partners Investment Advisory LLC purchased a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter valued at approximately $100,000. Parallel Advisors LLC lifted its stake in shares of Ionis Pharmaceuticals by 62.8% during the 2nd quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock valued at $109,000 after buying an additional 800 shares in the last quarter. Hanseatic Management Services Inc. lifted its stake in shares of Ionis Pharmaceuticals by 1.2% during the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock valued at $177,000 after buying an additional 41 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Ionis Pharmaceuticals by 9.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after buying an additional 311 shares in the last quarter. Finally, WFG Advisors LP lifted its stake in shares of Ionis Pharmaceuticals by 77.2% during the 2nd quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock valued at $193,000 after buying an additional 1,655 shares in the last quarter. Institutional investors own 91.58% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/01/ionis-pharmaceuticals-inc-ions-director-joseph-klein-iii-sells-3000-shares.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply